Novo Nordisk A/S (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 132   

Articles published

NVO 56.19 +1.22 (2.22%)
price chart
Is Novo Nordisk A/S (ADR) (NVO) Going to Burn These Hedge Funds?
Of the funds tracked by Insider Monkey, Renaissance Technologies holds the number one position in Novo Nordisk A/S (ADR) (NYSE:NVO). Renaissance Technologies has a $714.4 million position in the stock, comprising 1.7% of its 13F portfolio. Coming in ...
Healthcare Sector Active Runners: Novo Nordisk (NVO), Theravance (THRX ...  Techsonian (press release)
Novo Nordisk jumps 4.8% after Tresiba receives FDA approval
Novo Nordisk A/S ADR. NYSE: NVO. GO. Set Alerts · Find a Broker · Join TD Ameritrade · Market Index · Overview Profile News Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders.
Fundamental and Technical Report on Novo Nordisk A/S (ADR) (NYSE:NVO)
Novo Nordisk A/S (ADR) (NYSE:NVO) (TREND ANALYSIS) shares were traded with thin volume. The stock closed last trading session at $52.93, down by -1.07%, with a volume of 1,085,472 shares against an average volume for the last 3 months of ...
Novo Nordisk A/S (ADR) (NYSE:NVO) on Watch List
[The Motley Fool] Novo Nordisk A/S (ADR) (NYSE:NVO)(TREND ANALYSIS) Diabetes powerhouse Novo Nordisk A/S (ADR) (NYSE:NVO) recently presented impressive data on its type 2 diabetes drug candidate IDegLira. IDegLira is an investigational ...
Novo Nordisk A/S (ADR) Stock Surges On Increased Profit And Sales
Novo Nordisk A/S (ADR) (NYSE:NVO) announced its earnings for the first quarter of 2015 and the financial guidance for the full year 2015, and said that its current chief executive officer, Lars Rebien Sorensen, will remain at the helm of the company ...
Novo Nordisk CFO: U.S. Obesity Market Must Emerge, But It Will Take Time  Benzinga
Novo Nordisk profit rises; raises 2015 outlook  MarketWatch
Novo Nordisk A/S (ADR) Application For Insulin Drug Tresiba Accepted By FDA
Novo Nordisk A/S (ADR) (NYSE:NVO) has yet another victory to add to its long established success story in the diabetes market.
Novo Nordisk A/S (ADR) Anti-Obesity Drug Approved By European Commission
Novo Nordisk A/S (ADR) (NYSE:NVO), has another victory to add to its success story: its obesity drug Saxenda has won marketing authorization from the European Commission as announced on Monday.
Novo Nordisk A/S (ADR) Anticipates Price Gains For Its Insulin Drugs Even As ...
Novo Nordisk A/S (ADR) (NYSE:NVO) is optimistic about the company's ability to charge high prices for its diabetes products this year and the next year, despite increased competition in the market from Sanofi SA (ADR) (NYSE:SNY) as well as other ...
Novo Nordisk A/S, Sanofi SA, Merck & Co Top $62 Billion Diabetes Market In ...
According to a report compiled by data analytics firm GlobalData, the 10 leading diabetes drug-makers generated around $62 billion in 2014 global sales, up 5.1% year-over-year (YoY).
Novo Nordisk A/S (ADR) Shoots Up On Plans To Resubmit NDAs Of Tresiba And ...
Novo Nordisk A/S (ADR) (NYSE:NVO), the world's largest insulin-maker, announced Thursday its plans to resubmit New Drug Applications (NDAs) of its long-acting insulin candidate Tresiba and related drug Ryzodeg to the US Food and Drug Administration ...
Hot Stocks on the Run: Alibaba Group Holding Ltd (NYSE:BABA), Novo Nordisk A ...  wsnewspublishers